Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).

Autores de IIS La Fe

• 

  Bonaventura Casanova Estruch

  Autor

• Blanca Martínez De Las Heras

  Autor

• Federico Sanchez Domingo

  Autor

Participantes ajenos a IIS La Fe

• Fernandez O
• Alvarez-Cermeno JC
• Arroyo-Gonzalez R
• Brieva L
• Calles-Hernandez MC
• Comabella M
• Garcia-Merino JA
• Hernandez-Perez MA
• Izquierdo G
• Meca-Lallana JE
• Munoz-Garcia D
• Olascoaga J
• Oreja-Guevara C
• Prieto JM
• Ramio-Torrenta L
• Rodriguez-Antiguedad A
• Romero-Pinel L
• Tellez N
• Tintore M
• Montalban X
• Post-ECTRIMS group

Abstract

The new insights presented at the 5th Joint Triennial Congress of the European and Americas Committees on Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS) held in Amsterdam, the Netherlands, 19-22 October 2011, have been summarized at the fourth edition of Post-ECTRIMS meeting held in Madrid in November 2011. Regional grey-matter atrophy is more sensitive to cognitive impairment than global grey-matter atrophy measures. In patients with clinically isolated syndrome cognitive impairment does not predict conversion to multiple sclerosis (MS) after 5-years of follow-up. Focusing on central nervous system plasticity and functional reorganization in MS, an early intervention can improve clinical aspects and enhances brain plasticity. Preservation of a potential for plasticity provides a rationale for rehabilitation interventions even in later stages of disease. Therapeutical strategies have focused on stem cell-mediated remyelination and immunomodulation functions, on cellular infiltration into the brain, and on new ways for immuno-modulation for the development of future therapies in MS. Encouraging findings from clinical trials with current and emerging disease-modifying therapy being developed was also a key theme at this edition. Positive results have been reported for rituximab, ocrelizumab, ofatumumab, daclizumab, alemtuzumab, teriflunomide, BG-12, and laquinimod, including a favorable safety profile. Since armamentarium for the treatment of MS is fast increasing, concerns exist about the risk of severe adverse events with their use. This aspect reinforces the importance of disease registries as a proactive tool for monitoring drug safety in the post-approval setting.